Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 6


Oral and Poster Abstracts Oral 627. Aggressive Lymphomas: Clinical and Epidemiological: Clinical Management of Aggressive B cell NHL Adults, Translational Research, Lymphomas, Non-Hodgkin Lymphoma, Non-Biological, Clinical Research, B Cell Lymphoma, Chemotherapy, Clinically Relevant, Diseases, Real World Evidence, Aggressive Lymphoma, Therapies, Registries, Lymphoid...

  • 123456 Profile photo of Madelyn

    Analysis of 1,384 lymphoma patients treated with CNS prophylaxis compared intercalated HD MTX with end of treatment HD MTX. There was no difference seen in CNS relapse rates between the groups. When limited analysis to 600 high risk CNS IPI patients the 3 year CNS relapse rate was ~9% without a difference between the groups. Intercalated treatment was associated with delays in RCHOP delivery. Exploratory analysis on patients with isolated CNS relapse also showed no difference in relapse rates between treatment arms.